Literature DB >> 8824725

Distribution of TP53 mutations among acute leukemias with MLL rearrangements.

C Lanza1, G Gaidano, G Cimino, C Pastore, J Nomdedeu, G Volpe, C Vivenza, G Parvis, U Mazza, G Basso, E Madon, F Lo Coco, G Saglio.   

Abstract

Acute leukemias carrying MLL rearrangements are characterized by a high degree of clinical and immunologic heterogeneity, as demonstrated by variability in their immunophenotype, consistent with lymphoid or myeloid/monoblastic derivation, as well as their occurrence in distinct age groups from infancy to adulthood. Recently, it was shown that inactivation of the TP53 tumor suppressor gene occurs frequently in cases of acute lymphoblastic leukemia carrying MLL rearrangements. In order to assess the extent of TP53 inactivation throughout the immunophenotypic and clinical spectrum of MLL+ acute leukemias, we tested for TP53 mutations 29 cases of MLL+ acute leukemias displaying lymphoid (13 cases) or myeloid/monoblastic (16 cases) features and belonging to different age groups. Mutations were detected in 6/16 myeloid/monoblastic cases and in 3/13 lymphoid cases. Among myeloid/monoblastic leukemias, the TP53 mutations occurred in 3/4 infants, but only in 3/16 cases in other age groups. Overall, our data suggest that (1) TP53 inactivation is a relatively common event in leukemias with MLL rearrangements irrespective of the leukemic phenotype and of the patients' age; (2) at least two genetic lesions (i.e., MLL rearrangement and TP53 mutation) have accumulated in the short time (few weeks after the birth or conception of the child) corresponding to the development of acute leukemias of infancy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8824725     DOI: 10.1002/(SICI)1098-2264(199601)15:1<48::AID-GCC7>3.0.CO;2-4

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  4 in total

1.  The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogeneous leukemia.

Authors:  U Fuchs; G Rehkamp; O A Haas; R Slany; M Kōnig; S Bojesen; R M Bohle; C Damm-Welk; W D Ludwig; J Harbott; A Borkhardt
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 2.  The role of the MLL gene in infant leukemia.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

3.  A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines.

Authors:  Takeshi Inukai; Xiuru Zhang; Takeshi Kameyama; Yukiko Suzuki; Kazuhito Yoshikawa; Itaru Kuroda; Atsushi Nemoto; Koshi Akahane; Hiroki Sato; Kumiko Goi; Kazunori Nakamoto; Jun-ichi Hamada; Mitsuhiro Tada; Tetsuya Moriuchi; Kanji Sugita
Journal:  Am J Hematol       Date:  2010-07       Impact factor: 10.047

4.  The Phenomenon of Gene Rearrangement is Frequently Associated with TP53 Mutations and Poor Disease-Free Survival in Hepatocellular Carcinoma.

Authors:  Fu He; Kangjian Song; Ge Guan; Junyu Huo; Yang Xin; Tianxiang Li; Chao Liu; Qingwei Zhu; Ning Fan; Yuan Guo; Liqun Wu
Journal:  Pharmgenomics Pers Med       Date:  2021-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.